Lingshi Tan, Ph.D.
Executive Chairman of the Board
Lingshi Tan, Ph.D., now serves as the Executive Chairman of Caidya, having previously held the position of CEO. Dr. Tan will continue to provide strategic oversight and guidance, collaborating closely with the CEO, Barbara Lopez Kunz to ensure Caidya advances its mission of bringing life-changing therapies to the global community.
Dr. Tan is a visionary strategic leader who has set clear long-term development strategies, visions, and missions for Caidya. His focus on customer-centric, patient-centric, and innovation-driven professional services has established Caidya as a trusted partner for biotech and biopharma countries around the world who want to conduct global clinical research. Under Dr. Tan’s continued strategic oversight, Caidya will continue to bring life-changing therapies to our global community through liberated clinical research.
In 2016, Dr. Tan created dMed Clinical Company (dMed) to fulfill his vision of establishing a global CRO to liberate clinical research through listening for understanding, thinking openly, owning the success of each project conducted, and sharing the organization’s extensive knowledge every step of the way. In 2022, following a series of acquisitions, dMed established the brand name Caidya to reflect the consolidated global enterprise of strategic operations across 23 countries and regions, providing a full range of services to clients and patient populations across several therapeutic areas in the Americas, Europe, and Asia-Pacific.
Prior to founding dMed, Dr. Tan served for nearly 20 years in global management roles for Pfizer. After heading the Global Biometrics team for the LATAM, MEA and JAPAC Regions, Dr. Tan was tapped to serve as Pfizer’s VP of Worldwide Development Operations. During his time managing Pfizer’s worldwide development, Dr. Tan founded and served as General Manager of Pfizer (China) Research & Development Co., Ltd. (CRDC) which he grew from scratch to an organization of more than 1,000 professionals that became an integral part of Pfizer’s global R&D network.
Dr. Tan earned his PhD in Biostatistics from the University of Pittsburgh, and lives in Seattle, Washington. He was a member of the Drug Information Association (DIA) Global Board of Directors from 2016 to 2022, including serving as Chair. Dr. Tan continues to serve DIA as the Chair of Fellows.
